Deals: No IPO for Organon - Pharmaceutical Executive


Deals: No IPO for Organon
Akzo Nobel sells its pharma subsidiary to Schering-Plough. Plus, Jazz registers for an IPO, Eli Lilly acquires a sleep

Pharmaceutical Executive

Paradigm's major investors were BioOne Capital of Singapore, Avlar BioVentures, and Merlin Biosciences. Other shareholders include: Lloyds Development Capital, TTP Ventures, The Wellcome Trust, University of Cambridge, and Genmab A/S. Paradigm's shareholders received advice in the transaction from Avlar.


blog comments powered by Disqus

Source: Pharmaceutical Executive,
Click here